Century Therapeutics (IPSC) Other financing activities (2020 - 2021)
Century Therapeutics (IPSC) posted quarterly Other financing activities of $219.1 million for Q3 2021, up 164652.63% year-over-year from N/an in Q3 2020, and up 12587.96% quarter-over-quarter from $1.7 million in Q2 2021.
Powered by 
Analysis
Century Therapeutics (IPSC) Other financing activities (2020 - 2021) Analysis & Trends
Century Therapeutics (IPSC) has reported Other financing activities for 2 consecutive years, with $219.1 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Other financing activities rose 164652.63% year-over-year to $219.1 million; the TTM figure through Dec 2021 stood at $221.4 million (changed N/A YoY), while the FY2021 annual figure was $221.4 million, up 153651.39% from the prior year.
- Other financing activities rose to $219.1 million in Q3 2021 per IPSC's latest filing, from $1.7 million in the prior quarter.
- Across five years, Other financing activities topped out at $219.1 million in Q3 2021 and bottomed at $133000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | -476,000.00 |
| Jun 30, 2021 | 221.32 Mn |
| Mar 31, 2021 | 554,000.00 |
| Sep 30, 2020 | 133,000.00 |